Matches in SemOpenAlex for { <https://semopenalex.org/work/W4246325944> ?p ?o ?g. }
Showing items 1 to 57 of
57
with 100 items per page.
- W4246325944 endingPage "215" @default.
- W4246325944 startingPage "215" @default.
- W4246325944 abstract "Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes Joshua J Neumiller1, Travis E Sonnett2, Lindy D Wood1, Stephen M Setter1, R Keith Campbell21Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, Washington; 2Department of Pharmacotherapy, College of Pharmacy, Washington State University, Pullman, Washington, USAAbstract: Liraglutide is a glucagon-like peptide-1 analog with pharmacokinetic properties suitable for once-daily administration approved by the Food and Drug Administration for the treatment of patients with type 2 diabetes. Clinical trial data from large, controlled studies demonstrate the safety and efficacy of liraglutide in terms of hemoglobin A1c (HbA1c) reduction, reductions in body weight, and the drug’s low risk for hypoglycemic events when used as monotherapy. Liraglutide has been studied as monotherapy and in combination with metformin, glimepiride, and rosiglitazone for the treatment of type 2 diabetes. Additionally, comparative data with insulin glargine and exenatide therapy are available from Phase III trials. Once-daily administration may provide a therapeutic advantage for liraglutide over twice-daily exenatide, with similar improvements in HbA1c and body weight observed when liraglutide was compared with exenatide. The glucose-dependent mechanism of insulin release with incretin analog therapy holds potential clinical significance in the management of postprandial hyperglycemic excursions, with minimal risk of hypoglycemia when used with non-secretagogue medications. Data to date on patient-reported outcomes with liraglutide treatment are encouraging. The most common adverse events associated with liraglutide therapy are dose-dependent nausea, vomiting, and diarrhea. Diligent postmarketing surveillance to elucidate the risk of pancreatitis and medullary thyroid carcinoma in a heterogeneous population are likely warranted.Keywords: incretin analog, incretin effect, liraglutide, diabetes" @default.
- W4246325944 created "2022-05-12" @default.
- W4246325944 creator A5014627592 @default.
- W4246325944 creator A5087170338 @default.
- W4246325944 date "2010-07-01" @default.
- W4246325944 modified "2023-10-18" @default.
- W4246325944 title "Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes" @default.
- W4246325944 doi "https://doi.org/10.2147/dmsott.s7314" @default.
- W4246325944 hasPublicationYear "2010" @default.
- W4246325944 type Work @default.
- W4246325944 citedByCount "0" @default.
- W4246325944 crossrefType "journal-article" @default.
- W4246325944 hasAuthorship W4246325944A5014627592 @default.
- W4246325944 hasAuthorship W4246325944A5087170338 @default.
- W4246325944 hasBestOaLocation W42463259441 @default.
- W4246325944 hasConcept C126322002 @default.
- W4246325944 hasConcept C134018914 @default.
- W4246325944 hasConcept C2777180221 @default.
- W4246325944 hasConcept C2779306644 @default.
- W4246325944 hasConcept C2780152017 @default.
- W4246325944 hasConcept C2780323712 @default.
- W4246325944 hasConcept C2780533449 @default.
- W4246325944 hasConcept C2781308992 @default.
- W4246325944 hasConcept C500440147 @default.
- W4246325944 hasConcept C555293320 @default.
- W4246325944 hasConcept C71924100 @default.
- W4246325944 hasConcept C98274493 @default.
- W4246325944 hasConceptScore W4246325944C126322002 @default.
- W4246325944 hasConceptScore W4246325944C134018914 @default.
- W4246325944 hasConceptScore W4246325944C2777180221 @default.
- W4246325944 hasConceptScore W4246325944C2779306644 @default.
- W4246325944 hasConceptScore W4246325944C2780152017 @default.
- W4246325944 hasConceptScore W4246325944C2780323712 @default.
- W4246325944 hasConceptScore W4246325944C2780533449 @default.
- W4246325944 hasConceptScore W4246325944C2781308992 @default.
- W4246325944 hasConceptScore W4246325944C500440147 @default.
- W4246325944 hasConceptScore W4246325944C555293320 @default.
- W4246325944 hasConceptScore W4246325944C71924100 @default.
- W4246325944 hasConceptScore W4246325944C98274493 @default.
- W4246325944 hasLocation W42463259441 @default.
- W4246325944 hasOpenAccess W4246325944 @default.
- W4246325944 hasPrimaryLocation W42463259441 @default.
- W4246325944 hasRelatedWork W1589544939 @default.
- W4246325944 hasRelatedWork W1994806180 @default.
- W4246325944 hasRelatedWork W2050851282 @default.
- W4246325944 hasRelatedWork W2057332288 @default.
- W4246325944 hasRelatedWork W2058514432 @default.
- W4246325944 hasRelatedWork W2081995839 @default.
- W4246325944 hasRelatedWork W2460294411 @default.
- W4246325944 hasRelatedWork W4291003989 @default.
- W4246325944 hasRelatedWork W2186890147 @default.
- W4246325944 hasRelatedWork W2188732033 @default.
- W4246325944 isParatext "false" @default.
- W4246325944 isRetracted "false" @default.
- W4246325944 workType "article" @default.